Mark Aguillard
Corporate Officer/Principal bij DERMTECH, INC.
Vermogen: 63 180 $ op 31-03-2024
Profiel
Mark Aguillard is currently the Chief Commercial Officer at DermTech, Inc. He was previously the Chief Commercial Officer at Epic Sciences, Inc. from 2021 to 2023.
Aguillard received an undergraduate degree from Texas Tech University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
DERMTECH, INC.
0.26% | 20-09-2023 | 90 000 ( 0.26% ) | 63 180 $ | 31-03-2024 |
Actieve functies van Mark Aguillard
| Bedrijven | Functie | Begin |
|---|---|---|
| DERMTECH, INC. | Corporate Officer/Principal | 19-09-2023 |
Eerdere bekende functies van Mark Aguillard
| Bedrijven | Functie | Einde |
|---|---|---|
Epic Sciences, Inc.
 Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01-09-2023 |
Opleiding van Mark Aguillard
| Texas Tech University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| DERMTECH, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Epic Sciences, Inc.
Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Health Technology |
